Medicinal chemistry inspired fragment-based drug discovery

Methods in Enzymology

Volumn 493, Issue , 2011, Pages 421-445

  Lanter, James ^a   Zhang, Xuqing ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZISOTHIAZOL DERIVATIVE; BENZISOXAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INDAZOLE DERIVATIVE; KETOHEXOKINASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MEDIUM CHAIN FATTY ACID COENZYME A LIGASE 2B; PYRAZOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRAZOLOPYRIMIDINONE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL CHEMISTRY; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; ENZYME ACTIVITY; FLUORESCENCE CORRELATION SPECTROSCOPY; FRAGMENT BASED DRUG DESIGN; FUZZY LOGIC; HIGH THROUGHPUT SCREENING; HYDROPHILICITY; HYDROPHOBICITY; IC 50; ISOTHERMAL TITRATION CALORIMETRY; LEAD GENERATION; LIGAND BINDING; MASS SPECTROMETRY; MEDICINAL CHEMISTRY; MEDICINAL PLANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

EID: 79952372796     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381274-2.00016-9     Document Type: Chapter

References (17)

1. R.K. Bakshi, G.H. Rasmusson, G.F. Patel, R.T. Mosley, B. Chang, K. Ellsworth, G.S. Harris, and R.L. Tolman 4-Aza-3-oxo-5α -androst-1-ene-17β-N-arylcarboxamides as dual inhibitors of human type 1 and type 2 steroid 5α -reductases. dramatic effect of N-Aryl substituents on type 1 and type 2 5α -reductase inhibitory potency J. Med. Chem. 38 17 1995 3189 3192
2. S.D. Bembenek, B.A. Tounge, and C.H. Reynolds Ligand efficiency and fragment-based drug discovery Drug Discov. Today 14 5/6 2009 278 283
3. M. Boolell, M.J. Allen, S.A. Ballard, S. Gepi-Attee, G.J. Muirhead, A.M. Naylor, I.H. Osterloh, and C. Gingell Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction Int. J. Impot. Res. 8 2 1996 47 52
4. S.M. Drawz, and R.A. Bonomo Three decades of β-lactamase inhibitors Clin. Microbiol. Rev. 23 1 2010 160 201
5. D. Guenard, F. Gueritte-Voegelein, and P. Potier Taxol and taxotere : Discovery, chemistry, and structure-activity relationships Acc. Chem. Res. 26 4 1993 160 167
6. V.V. Hannah, C. Atmanene, D. Zeyer, A. Van Dorsselaer, and S. Sanglier-Cianferani Native MS: An 'ESI' way to support structure- and fragment-based drug discovery Future Med. Chem. 2 1 2010 35 50
7. C. Hansch, P.P. Maloney, T. Fujita, and R.M. Muir Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients Nature 194 1962 178 180
8. M.J. Hartshorn, C.W. Murray, A. Cleasby, M. Frederickson, I.J. Tickle, and H. Jhoti Fragment-based lead discovery using x-ray crystallography J. Med. Chem. 48 2 2005 403 413 (Pubitemid 40139783)
9. T. Hesterkamp, J. Barker, A. Davenport, and M. Whittaker Fragment based drug discovery using fluorescence correlation spectroscopy techniques: Challenges and solutions Curr. Top. Med. Chem. 7 16 2007 1582 1591 (Pubitemid 350138969)
10. J. Kling From hypertension to angina to Viagra: On its way to becoming Viagra, UK-92, 480 changed from a drug for hypertension to a drug for angina, and then changed again when a 10-day toleration study in Wales turned up an unusual side effect Mod. Drug Discov. 1 2 1998 31 3334, 36, 38
11. G. Kochan, E.S. Pilka, F. von Delft, U. Oppermann, and W.W. Yue Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme A synthetase ACSM2A J. Mol. Biol. 388 5 2009 997 1008
12. C.W. Murray, and D.C. Rees The rise of fragment-based drug discovery Nat. Chem. 1 3 2009 187 192
13. T. Neumann, H.-D. Junker, K. Schmidt, and R. Sekul SPR - based fragment screening: Advantages and applications Curr. Top. Med. Chem. 7 16 2007 1630 1642 (Pubitemid 350131018)
14. M. Orita, M. Warizaya, Y. Amano, K. Ohno, and T. Niimi Advances in fragment-based drug discovery platforms Expert Opin. Drug Discov. 4 11 2009 1125 1144
15. F.M. Raushel, and W.W. Cleland Bovine liver fructokinase: Purification and kinetic properties Biochemistry 16 10 1977 2169 2175 (Pubitemid 8120884)
16. G. Ravipati, J.A. McClung, W.S. Aronow, S.J. Peterson, and W.H. Frishman Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease Cardiol. Rev. 15 2 2007 76 86
17. Edward R. Zartler, and Huaping Mo Practical aspects of NMR-based fragment discovery Curr. Top. Med. Chem. 7 16 2007 1592 1599 (Pubitemid 350131016)